MarketCap
Facebook
X
Telegram
Motus GI Holdings Cost of Revenue | MOTS
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Motus GI Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 81 K | 198 K | 181 K | 95 K | 136 K | 54 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 198 K | 54 K | 124 K |
Quarterly Cost of Revenue Motus GI Holdings
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12 K | - | 22 K | 31 K | 9 K | - | 83 K | 68 K | 15 K | - | 65 K | 42 K | 28 K | - | 32 K | 10 K | 30 K | - | 62 K | 2 K | 1 K | - | 56 K | 41 K | 15 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 83 K | 1 K | 32.8 K |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
8.99 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
361 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
369 M | - | 0.12 % | $ 80.1 M | China |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B |  Niderland |
 |
Soleno Therapeutics
SLNO
|
2.7 M | - | - | $ 2.69 B | USA |
 |
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
5 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
3.08 M | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
1.44 B | - | -0.91 % | $ 14.7 B | USA |
 |
Psychemedics Corporation
PMD
|
12.6 M | - | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
23.6 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
T2 Biosystems
TTOO
|
21 M | - | -39.35 % | $ 313 K | USA |
 |
Renalytix AI plc
RNLX
|
2.13 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Syneos Health
SYNH
|
4.14 B | - | - | $ 4.46 B | USA |
 |
Meridian Bioscience
VIVO
|
145 M | - | - | $ 1.49 B | USA |
 |
Surmodics
SRDX
|
33 M | - | - | $ 608 M | USA |
 |
Agilent Technologies
A
|
3.3 B | $ 127.06 | 2.2 % | $ 36.1 B | USA |
 |
Biomerica
BMRA
|
4.81 M | $ 1.79 | -9.14 % | $ 4.11 M | USA |
 |
BioNano Genomics
BNGO
|
15.3 M | $ 1.14 | -1.72 % | $ 6.21 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
137 M | $ 7.25 | 2.98 % | $ 76.5 M | China |
 |
Bioventus
BVS
|
180 M | $ 8.71 | 1.99 % | $ 580 M | USA |
 |
Brainsway Ltd.
BWAY
|
10.4 M | $ 14.89 | 3.33 % | $ 506 M |  Israel |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 26.18 | 11.5 % | $ 1.4 B | USA |
 |
Co-Diagnostics
CODX
|
222 K | $ 3.37 | 1.2 % | $ 4.48 M | USA |
 |
Castle Biosciences
CSTL
|
71 M | $ 21.12 | 4.3 % | $ 612 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 195.0 | -1.4 % | $ 21.6 B | USA |
 |
Danaher Corporation
DHR
|
10 B | $ 177.17 | -0.33 % | $ 126 B | USA |
 |
DarioHealth Corp.
DRIO
|
9.69 M | $ 6.93 | -2.81 % | $ 27.6 M | Israel |
 |
DexCom
DXCM
|
1.86 B | $ 72.47 | 1.74 % | $ 28.3 B | USA |
 |
Fulgent Genetics
FLGT
|
192 M | $ 18.0 | 1.69 % | $ 554 M | USA |